BioLife Solutions, Inc. (BLFS) Financial Ratios
31 years of historical data (1995–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
↑
N/A
—
5yr avg: 397.43
30Y Low41.2·High56.8
P/FCF
↓
119.61
↓-30% vs avg
5yr avg: 170.19
30Y Low2.5·High172.5
P/B Ratio
↑
3.41
↑+23% vs avg
5yr avg: 2.76
30Y Low1.0·High67.9
ROE
↓
-3.4%
↓+74% vs avg
5yr avg: -12.8%
30Y Low-325%·High12%
Debt/EBITDA
↑
N/A
—
5yr avg: 11.41
30Y Low0.9·High19.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BLFS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioLife Solutions, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 119.6x P/FCF, 30% below the 5-year average of 170.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.3B | $1.2B | $1.2B | $710M | $773M | $1.4B | $1.1B | $315M | $196M | $80M | $20M |
| Enterprise Value | $1.3B | $1.2B | $1.1B | $716M | $797M | $1.4B | $1.0B | $310M | $165M | $73M | $22M |
| P/E Ratio → | -104.16 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 13.22 | 12.23 | 14.54 | 9.37 | 10.14 | 12.04 | 22.65 | 11.50 | 9.91 | 7.22 | 2.47 |
| P/B Ratio | 3.41 | 3.16 | 3.43 | 2.10 | 2.12 | 2.99 | 5.31 | 3.79 | 4.53 | 7.89 | 6.43 |
| P/FCF | 119.61 | 110.58 | 229.80 | — | — | — | 578.77 | 585.26 | 105.83 | 172.55 | — |
| P/OCF | 63.25 | 58.48 | 141.85 | — | — | — | 167.19 | 259.58 | 83.29 | 131.54 | — |
P/E links to full P/E history page with 30-year chart
BLFS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.07 | 13.75 | 9.44 | 10.46 | 11.68 | 21.00 | 11.32 | 8.35 | 6.62 | 2.65 |
| EV / EBITDA | — | — | 738.05 | — | 56.82 | — | 581.76 | 202.73 | 41.23 | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 402.30 | — | — | — |
| EV / FCF | — | 109.16 | 217.27 | — | — | — | 536.63 | 575.79 | 89.24 | 158.10 | — |
BLFS Profitability
Margins and return-on-capital ratios measuring operating efficiency
BioLife Solutions, Inc. earns an operating margin of -12.6%. Operating margins have expanded from -30.9% to -12.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -3.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.6% | 64.6% | 65.3% | 61.6% | 61.5% | 24.2% | 57.1% | 67.6% | 68.5% | 61.2% | 58.1% |
| Operating Margin | -12.6% | -12.6% | -8.7% | -30.9% | -7.8% | -29.5% | -6.9% | -2.9% | 18.5% | -9.6% | -59.0% |
| Net Profit Margin | -12.6% | -12.6% | -24.5% | -87.6% | -183.4% | -7.5% | 5.5% | -6.1% | 16.5% | -22.8% | -83.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.4% | -3.4% | -5.9% | -18.9% | -33.1% | -2.6% | 1.9% | -2.6% | 12.3% | -37.9% | -105.6% |
| ROA | -3.0% | -3.0% | -5.0% | -15.4% | -27.9% | -2.3% | 1.6% | -2.4% | 11.3% | -25.1% | -67.7% |
| ROIC | -2.8% | -2.8% | -1.7% | -4.8% | -1.1% | -9.4% | -2.5% | -1.3% | 34.5% | -19.7% | -68.4% |
| ROCE | -3.2% | -3.2% | -1.9% | -6.0% | -1.3% | -9.6% | -2.2% | -1.2% | 13.5% | -12.1% | -55.6% |
BLFS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $33M exceeds total debt of $18M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.09 | 0.10 | 0.12 | 0.06 | 0.05 | 0.02 | — | — | 0.90 |
| Debt / EBITDA | — | — | 19.70 | — | 3.11 | — | 6.42 | 0.89 | — | — | — |
| Net Debt / Equity | — | -0.04 | -0.19 | 0.02 | 0.07 | -0.09 | -0.39 | -0.06 | -0.71 | -0.66 | 0.45 |
| Net Debt / EBITDA | — | — | -42.57 | — | 1.73 | — | -45.68 | -3.33 | -7.66 | — | — |
| Debt / FCF | — | -1.42 | -12.53 | — | — | — | -42.14 | -9.47 | -16.59 | -14.45 | — |
| Interest Coverage | -3.46 | -3.46 | -9.92 | -14.15 | -15.54 | -63.19 | -199.28 | 154.00 | -5000.00 | -4.68 | -24.26 |
Net cash position: cash ($33M) exceeds total debt ($18M)
BLFS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
BioLife Solutions, Inc.'s current ratio of 5.94x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.63x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.86x to 5.94x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.94 | 5.94 | 4.54 | 2.86 | 3.11 | 2.95 | 7.37 | 3.11 | 19.37 | 6.56 | 4.08 |
| Quick Ratio | 4.63 | 4.63 | 3.66 | 1.83 | 2.32 | 2.28 | 6.62 | 1.68 | 17.56 | 5.34 | 2.53 |
| Cash Ratio | 3.87 | 3.87 | 3.19 | 1.05 | 1.41 | 1.64 | 5.81 | 0.83 | 15.81 | 4.40 | 1.24 |
| Asset Turnover | — | 0.24 | 0.21 | 0.18 | 0.17 | 0.22 | 0.20 | 0.29 | 0.43 | 0.91 | 1.04 |
| Inventory Turnover | 1.13 | 1.13 | 0.99 | 2.22 | 0.84 | 3.19 | 1.78 | 0.80 | 1.77 | 2.32 | 1.96 |
| Days Sales Outstanding | — | 30.17 | 40.68 | 89.77 | 162.47 | 71.12 | 60.77 | 71.28 | 56.30 | 33.81 | 52.96 |
BLFS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioLife Solutions, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 0.2% | 0.1% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.8% | 0.9% | 0.4% | — | — | — | 0.2% | 0.2% | 0.9% | 0.6% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.2% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% | 0.1% | 0.0% |
| Shares Outstanding | — | $49M | $46M | $44M | $42M | $39M | $27M | $19M | $16M | $13M | $13M |
Peer Comparison
Compare BLFS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BLFSYou | $1B | -104.2 | — | 119.6 | 64.6% | -12.6% | -3.4% | -2.8% | — |
 BFLY | $2B | -28.7 | — | — | 46.9% | -88.5% | -42.2% | -76.8% | — |
 AZTA | $1B | -19.1 | 18.1 | 28.0 | 45.5% | -1.9% | -3.2% | -0.5% | 2.2 |
 CYRX | $753M | 10.7 | — | — | 47.1% | -20.9% | 15.5% | -5.1% | — |
 RGEN | $7B | 153.5 | 54.7 | 79.3 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 NVST | $4B | 92.5 | 13.8 | 18.3 | 55.0% | 8.3% | 1.6% | 4.8% | 5.0 |
 FELE | $5B | 32.1 | 14.4 | 23.8 | 35.5% | 12.7% | 11.3% | 14.7% | 0.8 |
 BNGO | $4M | -0.2 | — | — | 22.0% | -116.9% | -66.2% | -49.1% | — |
 FLGT | $535M | -9.1 | — | — | 40.6% | -28.2% | -5.4% | -6.4% | — |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BLFS — Frequently Asked Questions
Quick answers to the most common questions about buying BLFS stock.
What is BioLife Solutions, Inc.'s P/E ratio?
BioLife Solutions, Inc.'s current P/E ratio is -104.2x. The historical average is 6.0x.
What is BioLife Solutions, Inc.'s ROE?
BioLife Solutions, Inc.'s return on equity (ROE) is -3.4%. The historical average is -79.3%.
Is BLFS stock overvalued?
Based on historical data, BioLife Solutions, Inc. is trading at a P/E of -104.2x. Compare with industry peers and growth rates for a complete picture.
What are BioLife Solutions, Inc.'s profit margins?
BioLife Solutions, Inc. has 64.6% gross margin and -12.6% operating margin.